Free tool
FAERS Monitor: Maxalt-Mlt
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020865 or its brand name (Maxalt-Mlt, Rizatriptan Benzoate). Reports on generic versions are filed under their own applications.
Reports
2,429
Serious
1,490
61% of reports
Hospitalization
512
Death reported
55
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective469
- headache324
- nausea309
- migraine274
- off label use270
- fatigue198
- drug intolerance185
- hypersensitivity184
- product use in unapproved indication179
- diarrhoea141
- pain139
- vomiting135
- swelling face134
- dysphonia133
- swollen tongue130
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 10 |
| 2005 | 13 |
| 2006 | 18 |
| 2007 | 35 |
| 2008 | 43 |
| 2009 | 44 |
| 2010 | 41 |
| 2011 | 49 |
| 2012 | 43 |
| 2013 | 55 |
| 2014 | 56 |
| 2015 | 121 |
| 2016 | 214 |
| 2017 | 134 |
| 2018 | 153 |
| 2019 | 181 |
| 2020 | 154 |
| 2021 | 126 |
| 2022 | 198 |
| 2023 | 187 |
| 2024 | 203 |
| 2025 | 205 |
| 2026 | 146 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,730 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| swollen tongueSignal | 130 | 36.2 | 30.6 | 4,401 |
| migraineSignal | 274 | 24.9 | 22.3 | 6,278 |
| dysphoniaSignal | 133 | 19.7 | 16.7 | 2,348 |
| swelling faceSignal | 134 | 17.9 | 15.1 | 2,117 |
| drug intoleranceSignal | 185 | 16.6 | 14.5 | 2,706 |
| hypersensitivitySignal | 184 | 8.6 | 7.5 | 1,236 |
| product use in unapproved indicationSignal | 179 | 6.3 | 5.4 | 794 |
| headacheSignal | 324 | 4.5 | 4.0 | 898 |
| nauseaSignal | 309 | 3.4 | 3.0 | 536 |
| drug ineffectiveSignal | 469 | 3.1 | 2.8 | 701 |
| off label useSignal | 270 | 2.7 | 2.4 | 293 |
| vomitingSignal | 135 | 2.5 | 2.1 | 121 |
| fatigueSignal | 198 | 2.2 | 1.9 | 134 |
| pain | 139 | 2.0 | 1.7 | 66 |
| diarrhoea | 141 | 1.9 | 1.6 | 60 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.